Research Shows Significant Link Between Patient Recruitment Methods and Subject Retention in Clinical Trials
KING OF PRUSSIA, Pa., May 7, 2015 /PRNewswire/ -- A new white paper from MediciGlobal, "Clinical Retention Meta-Analysis" shows that patients who actively sought clinical trial involvement through MediciGlobal's online recruitment model had a 38% lower relative risk of drop out across four studies compared to those who were recruited by sites, with divergence across visits. An excerpted edition of the white paper will be published in the June, 2015 issue of DIA Forum.
The primary outcome for the meta-analysis measure was retention rates of subjects recruited comparing the two methods of engagement, online versus site databases. A secondary outcome was retention rates across all study visits to determine divergence patterns between the two groups.
Using PRISMA guidelines, systematic searches of MEDLINE, the Cochrane Library and the Educational Resources information center were performed and analyzed to validate MediciGlobal's findings.
"Efficient patient recruitment and effective patient retention in clinical trials is critical to clinical trial success. MediciGlobal prides itself on active and extensive patient engagement – it's gratifying to see that translate into quality patient referrals and subsequently higher retention rates," said Liz Moench, President and CEO of MediciGlobal.
MediciGlobal uses a detailed online pre-screening method to match patients to study inclusion/exclusion criteria, coupled with additional contact by a nurse for second level pre-screening prior to being referred to a study site.
Katrina Morgan, Clinical Research Coordinator for Dr. Lazlo Mate, Neurologist in West Palm Beach, Florida commented that "Medici's pre-screening is thorough and helpful to our site in finding potential subjects that meet criteria protocol. The depth of patient engagement has had a positive impact on retention."
Higher retention levels of subjects actively engaged in seeking out a clinical trial compared to those who were passively engaged via the physician or study staff may be related to different motivations between the groups of patients, especially since patients that seek out the study online must also undergo an additional step in MediciGlobal's comprehensive vetting procedure used on the active group. Additional research is necessary to further understand the drivers of these differences.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
